查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1630954

全球Omega-3處方藥市場：市場規模、佔有率和趨勢分析（按藥物、應用、分銷管道、地區和細分市場，2025-2030 年）

Omega 3 Prescription Drugs Market Size, Share & Trends Analysis Report By Drug (Vascepa, Lovaza), By Application (Cardiovascular), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

Omega-3處方藥市場的成長與趨勢：

預計到 2030 年，全球Omega-3處方藥市場規模將達到 18 億美元，到 2030 年的複合年成長率為 4.90%。

該行業的成長歸因於心血管疾病（CVD）病例的增加和飲食習慣的改變。已知血液三酸甘油酯水平升高與心血管疾病風險增加有關。根據歐洲心臟學會 2021 年的數據，每年有 1,790 萬人死於心血管疾病，是全球第一大死因。此外，由於Omega-3的藥物預計將推動成長。

例如，2020年，美國FDA核准了美國 Pharmaceuticals公司生產的Omega-3藥物VASCEPA的新的心血管適應症和擴大的標籤。三酸甘油酯升高會導致動脈狹窄，增加心臟病發作和中風的風險。胰臟炎，即胰臟的炎症，也可能因極高的水平而導致。糖尿病和肥胖是普遍存在的問題，會導致三酸甘油酯水平升高。平均而言，25％的美國成年人血液中的酒精含量處於邊緣高水平。只有經美國FDA核准，三酸甘油酯水平達到 500 mg/dl 或更高時才可以Omega-3脂肪酸藥物。在新冠肺炎疫情期間，處方Omega-3藥物的市場波動較大。

這是因為它在心血管疾病患者的管理中發揮著重要作用。例如，2021 年 8 月，Woodward Pharma Services LLC 宣布已從葛蘭素史克收購了 LOVAZA。該公司還旨在教育消費者和醫療保健提供者，以增加該產品的採用率。此外，目前正在進行多項降低三酸甘油酯的研究和開發研究。對 17 項針對升高三酸甘油酯水平的隨機臨床試驗結果的綜合分析表明，處方Omega-3脂肪酸藥物可使三酸甘油酯水平降低 20-30%。預計這將導致該產品的需求量增加。

Omega-3處方藥市場：分析概述

  • 預計 Lovaza 在預測期內將經歷中等的成長機會。
  • 心血管疾病將佔據市場主導地位，到 2024 年將佔據 86.8% 的最大收益佔有率。
  • 零售藥局將主導市場，由於其廣泛的可及性和消費者的便利性，到 2024 年將佔據 53.6% 的最大收益佔有率。
  • 由於消費者越來越偏好便捷、易得的醫療保健解決方案，預計線上藥局產業將經歷溫和成長。
  • 到 2024 年，北美將佔據全球Omega-3處方藥市場的 42.9% 佔有率，預計在預測期內將大幅成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章Omega-3處方藥市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • Omega-3處方藥市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章Omega-3處方藥市場：按藥物分類的估計和趨勢分析

  • 細分儀表板
  • Omega-3處方藥市場：藥物波動分析
  • Omega-3處方藥市場（依藥物類型）
  • 市場規模預測及趨勢分析（2018-2030年）
  • 瓦什帕
  • 洛瓦札
  • 其他

第 5 章Omega-3處方藥市場：按應用進行的估計和趨勢分析

  • 細分儀表板
  • Omega-3處方藥市場：應用趨勢分析
  • Omega-3處方藥市場應用前景
  • 市場規模預測及趨勢分析（2018-2030年）
  • 心血管
  • 其他

第 6 章Omega-3處方藥市場：按分銷管道進行的評估和趨勢分析

  • 細分儀表板
  • Omega-3處方藥市場：通路變化分析
  • Omega-3處方藥市場前景（依分銷管道）
  • 市場規模預測及趨勢分析（2018-2030年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 7 章Omega-3處方藥市場：區域估計與趨勢分析

  • 區域控制面板
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的近期趨勢和影響分析
  • 各公司市場佔有率分析（2024 年）
  • 主要企業簡介
    • Amarin Pharmaceuticals Ireland Limited
    • Woodward Pharma Services LLC
    • Mankind Pharma
    • GLW Pharma GMBH
    • CSPC Pharmaceutical Group Limited
    • Sofgen
    • WILSHIRE PHARMACEUTICALS, INC.
    • Sun Pharmaceutical Industries Ltd.
    • PuraCap Pharmaceutical LLC
    • ChartwellPharma
    • Amneal Pharmaceuticals LLC
Product Code: GVR-4-68039-963-4

Omega 3 Prescription Drugs Market Growth & Trends:

The global omega 3 prescription drugs market size is expected to reach USD 1.80 billion in 2030 and is expected to expand at a CAGR of 4.90% by 2030. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.

Omega 3 Prescription Drugs Market Report Highlights:

  • Lovaza is projected to experience moderate growth opportunities during the forecast period.
  • Cardiovascular dominated the market and accounted for the largest revenue share of 86.8% in 2024
  • Retail pharmacy dominated the market and accounted for the largest revenue share of 53.6% in 2024 due to its wide accessibility and consumer convenience
  • The online pharmacy segment is expected to witness moderate growth due to the increasing consumer preference for convenient and accessible healthcare solutions
  • North America dominated the global omega 3 prescription drugs market with a share of 42.9% in 2024 and is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Application
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Omega 3 Prescription Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
      • 3.2.1.2. Growing Awareness of Omega-3 Health Benefits
      • 3.2.1.3. Advancements in Pharmaceutical Formulations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Prescription Omega-3 Drugs
      • 3.2.2.2. Regulatory and Reimbursement Challenges
  • 3.3. Omega 3 Prescription Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Omega 3 Prescription Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Omega 3 Prescription Drugs Market: Drug Movement Analysis
  • 4.3. Omega 3 Prescription Drugs Market by Drug (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Vascepa
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Lovaza
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Omega 3 Prescription Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Omega 3 Prescription Drugs Market: Application Movement Analysis
  • 5.3. Omega 3 Prescription Drugs Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Cardiovascular
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Omega 3 Prescription Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Omega 3 Prescription Drugs Market by Distribution Channel Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospital Pharmacy
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Retail Pharmacy
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Online Pharmacy
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Omega 3 Prescription Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Amarin Pharmaceuticals Ireland Limited
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Woodward Pharma Services LLC
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Mankind Pharma
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. GLW Pharma GMBH
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. CSPC Pharmaceutical Group Limited
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Sofgen
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. WILSHIRE PHARMACEUTICALS, INC.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Sun Pharmaceutical Industries Ltd.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. PuraCap Pharmaceutical LLC
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ChartwellPharma
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Amneal Pharmaceuticals LLC
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Omega 3 Prescription Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 6 Global Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 7 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 10 North America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 11 North America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 14 U.S. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 17 Canada Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Mexico Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 19 Mexico Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 20 Mexico Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Europe Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 23 Europe Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 24 Europe Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 26 UK Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 27 UK Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Germany Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 29 Germany Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 30 Germany America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 France Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 33 France Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Spain Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 35 Spain Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 36 Spain Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Italy Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 Italy Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 39 Italy Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 41 Denmark Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 42 Denmark Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Sweden Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Sweden Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 45 Sweden Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Norway Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 47 Norway Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 48 Norway Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 China Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 54 China Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 55 China Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Japan Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 Japan Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 58 Japan Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 India Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 60 India Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 61 India Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 South Korea Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 South Korea Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 64 South Korea Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Australia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 66 Australia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 67 Australia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Thailand Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 Thailand Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 70 Thailand Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 Latin America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 Latin America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 74 Latin America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Brazil Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 76 Brazil Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 77 Brazil Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Argentina Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 Argentina Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 80 Argentina Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 MEA Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 MEA Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 83 MEA Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 84 MEA Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 South Africa Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 South Africa Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 87 South Africa Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 UAE Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 92 UAE Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 93 UAE Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Omega 3 Prescription Drugs Market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Omega 3 Prescription Drugs Market: Drug outlook and key takeaways
  • Fig. 10 Omega 3 Prescription Drugs Market: Drug movement analysis
  • Fig. 11 Vascepa market, 2018 - 2030 (USD Million)
  • Fig. 12 Lovaza market, 2018 - 2030 (USD Million)
  • Fig. 13 Others market, 2018 - 2030 (USD Million)
  • Fig. 14 Omega 3 Prescription Drugs Market: Application outlook and key takeaways
  • Fig. 15 Omega 3 Prescription Drugs Market: Application movement analysis
  • Fig. 16 Cardiovascular market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Omega 3 Prescription Drugs Market: Distribution channel outlook and key takeaways
  • Fig. 19 Omega 3 Prescription Drugs Market: Distribution channel movement analysis
  • Fig. 20 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 North America omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Canada omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Mexico omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Denmark omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Sweden omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Norway omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 MEA omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 List of key emerging company's/disruptors/innovators